Table 5.

Comparison of clinical parameters between UMOD positive and negative patients with ADTKD

Clinical parameter	UMOD positive	UMOD negative	Significance level (p < 0.0036)
Age at presentation [years]	9–57, median 39, n = 21	23–80, median 49, n = 20	p = 0.024*
Age at RRT [years]	27–66, median 47, n = 27	27–83, median 51.5, n = 16	p = 0.606*
Gout	15/33 patients (45%)	10/25 patients (40%)	p = 0.678**
Allopurinol use	13/35 patients (37%)	6/25 patients (24%)	p = 0.281**
Hypertension at presentation	31/35 patients (89%)	22/25 patients (88%)	p = 1.0***
Hyperuricaemia (Uric acid > 0.35 umol/l)	24/26 patients (92%)	15/19 patients (79%)	p = 0.377***
Uric Acid [mg/dl]	4.71–13.28, median 7.75, n = 25	4.54–12.27, median 8.07, n = 19	p = 0.61*
Proteinuria	8/22 patients (36%)	6/17 patients (35%)	p = 0.945**
Protein Creatinine Ratio [mg/g]	0–2761, median 234.5, n = 18	53–2469, median 624, n = 14	p = 0.065*
Anaemia pre RRT (Hb < 100 g/l)	4/27 patients (15%)	7/22 patients (32%)	p = 0.185***
Microscopic haematuria	1/27 patients (4%)	1/19 patients (5%)	p = 1.0***
Renal cysts	4/21 patients (19%)	4/15 patients (27%)	p = 0.694***
Normal renal size at presentation (renal diameter > 9 cm)	11/23 patients (48%)	12/19 patients (63%)	p = 0.32**
Electrolyte abnormalities	6/32 patients (19%)	1/22 patients (5%)	p = 0.22***

* = Mann Whitney U, ** = χ², *** = Fisher’s Exact test